Targeted Tumor Cytotoxicity Mediated by Intracellular Single-Chain Anti-oncogene Antibodies

Advances in Pharmacology

Volumn 40, Issue C, 1997, Pages 51-84

  Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY;

ANIMAL; CYTOTOXICITY; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; ONCOGENE; REVIEW;

ANIMALS; ANTIBODIES, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ONCOGENES;

EID: 0030624401     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60137-4     Document Type: Article

References (76)

1. Sikora K. Gene therapy for cancer. Trends Biotechnol. 11 (1993) 197-201
2. Dorudi S., Northover J.M.A., and Vile R.G. Gene transfer therapy in cancer. Br. J. Surg. 80 (1993) 566-572
3. Freeman S.M., and Zwiebel J.A. Gene therapy of cancer. Cancer Invest. 11 (1993) 676-688
4. Vanchieri C. Opportunities "opening up" for gene therapy. J. Natl. Cancer Inst. 85 (1993) 90-91
5. Lemoine N., and Sikora K. Interventional genetics and cancer treatment. Br. Med. J. 306 (1993) 665-666
6. Gutierrez A.A., Lemoine N.R., and Sikora K. Gene therapy for cancer. Lancet 339 (1992) 715-721
7. Karp J.E., and Broder S. New directions in molecular medicine. Cancer Res. 54 (1994) 653-665
8. Rosenberg S.A., Anderson W.F., Blaese M., Hwu P., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Ettinghausen S.E., Parkinson D.N., and White D.E. The development of gene therapy for the treatment of cancer. Ann. Surg. 218 (1993) 455-464
9. Baker S.J., Markowitz S., Fearon E.R., Willson J.K.V., and Volgelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249 (1990) 912-915
10. Huang H.-J.S., Yee J.-K., Shew J.-Y., Chen P.-L., Bookstein R., Friedmann T., Lee E.Y., and Lee W.-H. Suppression of neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242 (1988) 1563-1566
11. Bookstein R., Shew J.-Y., Chen P.-L., Scully P., and Lee W.-H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247 (1990) 712-716
12. Fujiwara T., Grimm E.A., Mukhopadhyay T., Cai D.W., Owen-Schaub L.B., and Roth J.A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53 (1993) 4129-4133
13. Zhan W.-W., Fang X., Mazur W., French B.A., Georges R.N., and Roth J.A. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1 (1994) 5-13
14. Fueyo J., Gomez-Manzano C., Yung W.K.A., dayman G.L., Liu T.-J., Bruner J., Levin V.A., and Kyritisis A.P. Adenovirus-mediated pl6/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12 (1996) 103-110
15. Krol A.V., Mol J.N.M., and Stuitje A.R. Modulation of eukaryotic gene expression by complement RNA or DNA sequences. Bio Techniques 6 (1988) 958-976
16. Helene C., and Toulme J.-J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta 104 (1990) 99-125
17. Zon G. Oligonucleotide as potential chemotherapeutic agents. Pharm. Res. 5 (1988) 539-549
18. Stein C.A., and Cheng Y.-C. Antisense oligonucleotides as therapeutic agents-Is the bullet really magic?. Science 261 (1993) 1004-1012
19. Wickström E.L., Bacon T.A., Gonzalez A., Freeman D.L., Lyman G.H., and Wickström E. Human promyelocytic leukemia HL-60 cell proliferation and c-Myc protein expression are inhibited by antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1028-1032
20. Kashani-Sabet M., Funato T., Florenes V.A., Fodstad O., and Scanlon K.J. Suppression of a neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 54 (1994) 900-902
21. Ebbinghaus S.W., Gee J.E., Rodu B., Mayfield C.A., Sanders G., and Miller D.M. Triplex formation inhibits HER-2/neu transcription in vivo. J. Clin. Invest. 92 (1993) 2433-2439
22. Haseloff J., and Gerlach W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (London) 334 (1988) 585-591
23. Kashani-Sabet M., Funato T., Tone T., Jiao L., Wang W., and Yoshida E. Reversal of the malignant phenotype by an anti-ras ribosome. Antisense Res. Dev. 2 (1992) 3-15
24. Ratahczak M.Z., Kant J.A., Luger S.M., Hijiya N., Zhang J., Zon G., and Gerwirtz A.M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 11823-11827
25. Georges R.N., Mukhopadhyay T., Zhang Y., Yen N., and Roth J.A. Prevention of orthotopic human lung cancer growth by intratreacheal instillation of a retroviral antisense K-ras construct. Cancer Res. 53 (1993) 1743-1746
26. Iverson P.L., Zhu S., Meyer A., and Zon G. Cellular uptake and subcellular distribution of phosphorothioate into cultured cells. Antisense Res. Dev. 2 (1992) 211-222
27. Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., and Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7031-7035
28. Bergan R., Connell Y., Fahmy B., and Neckers L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 21 (1993) 3567-3573
29. Theuer C.P., and Pastan I. Immunotoxins and recombinant toxins in the treatment of solid carcinomas. Am. J. Surg. 166 (1993) 284-288
30. Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., and Pastan I. B3-(Fv)-PE38KDEL, a single chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 8616-8620
31. Colcher D., Bird R., Roselli M., Hardmann K.M., Johnson S., Pope S., Dodd S.W., Pantoliano M.W., Milenic D.E., and Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 82 (1990) 1191-1197
32. Wawrzynczak E.J. Rational design of immunotoxins: Current progress and future prospects. Anti-Cancer Drug Des. 7 (1992) 427-441
33. Mykebust A.T., Godal A., and Fodstad O. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell cancer. Cancer Res. 54 (1994) 2146-2150
34. Friedman P.N., Chance D.F., Trail P.A., and Siegall C.B. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J. Immunol. 150 (1993) 3054-3061
35. res single chain Fv fragments inhibits meiotic maturation of Xenopus oocytes. Biochem. Biophys. Res. Commun. 197 (1993) 422-427
36. Marasco W.A., Haseltine W.A., and Chen S.-Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 7889-7893
37. Chen S.-Y., Bagley J., and Marasco W.A. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. 5 (1994) 595-601
38. ras protein. FEBS Lett. 274 (1990) 193-198
39. Yarden Y., and Ullrich A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57 (1988) 443-478
40. Hudziak R.M., Schlessinger J., and Ulrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7159-7163
41. Muller W.J., Sinn E., Pattengale P.K., Wallace R., and Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54 (1988) 105-115
42. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., and Keith D.E. Studies of the HER-2/neu proto-oncogene in the human breast and ovarian cancer. Science 244 (1989) 707-712
43. Hynes N.E. Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Cancer Biol. 4 (1993) 19-26
44. Giovanella B.C., Vardeman D.M., Williams L.J., Taylor D.J., Deipolyi P.D., Greef P.J., Stehlin J.S., Ullrich A., Cailleau R., Slamon D.J., and Gary H.E. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of HER-2/Neu oncogene. Int. J. Cancer 47 (1991) 66-71
45. Drebin J.A., Link V.C., and Greene M.I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2 (1988) 387-394
46. Fendley B.M., Winget M., Hudziak R.M., Lipari M.T., Naperi M.A., and Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50 (1990) 1550-1558
47. Carter P., Presta L., Gorman C.M., Ridgeway J.B.B., Henner D., Wong W.L.T., Rowland A.M., Kotts C., Carver M.E., and Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4285-4289
48. Hurwitz E., Stancovski I., Sela M., and Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3353-3357
49. De Santes K., Slamon D., Anderson S.K., Shepard M., Fendly B., Maneval D., and Press O. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res. 52 (1992) 1916-1923
50. Batra J.K., Kazpryzyk P.G., Bird R.E., Pastan I., and King C.R. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 5867-5871
51. Bertram J., Kalian M., Brysch W., Schlingensiepen K.-H., and Kneba M. Reduction of erbB-2 gene product in mammary carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochem. Biophys. Res. Cotnmun. 200 (1994) 661-667
52. Brysch W., Magal E., Louis J.-C., Knust M., Klinger I., and Schlinggensiepen R. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation. Cancer Gene Ther. 1 (1994) 99-105
53. Curiel D.T., Wagner E., Cotten M., Birnsteil M.L., Li C.-M., Loechel S., Agarwal S., and Hu P.-C. High efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes via an antibody bridge. Hum. Gene Ther. 3 (1992) 147-154
54. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., and Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133 (1984) 1710-1715
55. Hinshaw V.S., Olsen C.W., Dybhahl-Sissoko N., and Evans D. Apoptosis: A mechanism of cell killing by influenza A and B viruses. J. Virol. 68 (1994) 3667-3673
56. Duke R.C., and Cohen J.J. Morphological and biochemical assays of apoptosis. Curr. Protocols, Suppl. 3 (1992)
57. Vaux D.L. Toward an understanding of the molecular mechanisms of physiological cell death. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 786-789
58. Williams G.T. Programmed cell death: Apoptosis and oncogenesis. Cell (Cambridge, Mass.) 65 (1991) 1097-1098
59. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
60. Steller H. Mechanisms and genes of cellular suicide. Science 267 (1995) 1445-1449
61. Carson W.E., Haldar S., Baiocchi R.A., Croce C.M., and Caligiuri M.A. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 7553-7557
62. Miyashita T., and Reed J.C. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52 (1992) 5407-5411
63. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 (1993) 151-157
64. Kraus M.H., Popescu N.C., Amsbaugh S.C., and Kin C.R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6 (1987) 605-610
65. Hynes N.E., Gerber H.A., Saurer S., and Groner B. Overexpression of the c-erbB-2 protein in human breast tumor lines. J. Cell. Biochem. 39 (1989) 167-173
66. Iglehart J.D., Kraus M.H., Langton B.C., Huper G., Kerns B.J., and Marks J.R. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res. 50 (1990) 6701-6707
67. Kern J.A., Schwartz D.A., Nordberg J.E., Werner D.B., Greene M.I., Torney L., and Robinson R.A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50 16 (1990) 5184-5187
68. Hancock M.C., Langton B.C., Chan T., Toy P., Monahan J.J., Mischak R.P., and Shawver L.K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51 (1991) 4575-4580
69. Arteaga C.L., Winnier A.R., Poirier M.C., Lopez-Larraza D.M., Shawver L.K., Hurd S.D., and Stewart S.J. p185c-erbB-2 singaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 54 (1994) 3758-3765
70. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., and Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 (1994) 1829-1838
71. Graus-Porta D., Beerli R.R., and Hynes N.E. Single-chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15 (1995) 1182-1191
72. Deshane J., Cabrera G., Grim J.E., Siegal G.P., Pike J., and Alvarez R.D. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single chain antibody. Gyn. Onc. 59 (1995) 8-14
73. Deshane J., Loechel F., Conry R.M., Siegal G.P., King C.R., and Curiel D.T. Intracellular single-chain antibody directed against erbB-2 down-regulates cell surface erbB-2 and exhibits a selective anti-proliferative effect in erbB-2 overexpressing cancer cells lines. Gene Ther. 1 (1994) 332-337
74. Deshane J., Grim J., Loechel S., Siegal G., Alvarez R.D., and Curiel D.T. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther. 3 (1996) 89-98
75. Deshane J., Siegal G.P., Alvarez R.D., Wang M.H., Feng M., Cabrera G., Liu T., Kay M., and Curiel D.T. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96 (1995) 2980-2989
76. Grim J., Deshane J., Feng M., Lieber A., Kay M., and Curiel D.T. erbB-2 knock-out employing an intracellular single-chain antibody (sF) accomplishes specific toxicity in erbB-2 expressing lung cancer cell. Am. J. Respir. Cell Mol. Biol. 15 (1996) 348-354